Tumour Lysis Syndrome and Partial Remission Occurring After Administration of a Test Dose of Obinutuzumab
Chronic lymphocytic leukaemia (CLL) is one of the most common haematological malignancies worldwide, with an increasing prevalence in the elderly population. Obinutuzumab is a type II anti-CD20 monoclonal antibody which showed superiority over rituximab in combination chemotherapy with chlorambucil...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2017-01-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Subjects: | |
| Online Access: | http://ejcrim.com/index.php/EJCRIM/article/view/516 |